Breakthrough Study Reveals Two Common Drugs Could Potentially Reverse Fatty Liver Disease-Hope for Millions!
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as fatty liver disease, has emerged as the most prevalent liver condition globally, affecting approximately one in three adults. This disease arises when excess fat accumulates within liver cells, posing serious health risks, including liver damage and an increased likelihood of heart disease.
Promising new research from the University of Barcelona offers hope for innovative treatment options using existing medications. Led by Professor Marta Alegret, the study investigates the effects of two drugs, pemafibrate and telmisartan, which have shown significant potential in reducing liver fat in animal models suffering from MASLD. The combination of these medications not only appears to enhance liver health but may also mitigate related cardiovascular risks, presenting a potentially safer and more effective strategy than many experimental therapies.
Despite limited treatment options for MASLD, experts are increasingly looking toward drug repurposing as a viable solution. This approach entails utilizing already-approved medications for other conditions to expedite the treatment process. Marta Alegret explains, “We have focused on early stages of the disease to prevent progression. A drug must have a good safety profile to be considered.” The research team specifically examined pemafibrate, a lipid-lowering agent marketed in Japan, and the widely used blood pressure medication telmisartan. Both are known to help manage cardiovascular risk, a significant concern for MASLD patients.
To assess the drugs’ effectiveness, researchers conducted experiments on rats and zebrafish larvae-models chosen for their metabolic similarities to humans. The results were striking, revealing that the combination therapy significantly reversed liver fat accumulation induced by high-fat, high-fructose diets. Remarkably, administering half doses of each drug produced effects comparable to full doses of either agent alone. “Combination therapy may be more effective than monotherapy, leading to synergistic effects and reduced toxicity,” Alegret notes.
Furthermore, the treatment showed potential in lowering blood pressure and cholesterol levels, thereby diminishing overall cardiovascular risk. The study uncovered novel insights into the drugs’ mechanisms, revealing that telmisartan’s role in fat reduction is linked to the PCK1 protein. This protein, found at reduced levels in the livers of MASLD-affected animals, influences nutrient processing. “Telmisartan restores PCK1 levels, redirecting the metabolic flux from fat synthesis to glucose production,” explains Alegret. Interestingly, this increase in glucose production did not lead to elevated blood sugar levels, alleviating concerns about possible diabetes.
While these findings are promising, it’s important to note that the research is still in preliminary stages and requires further validation through clinical studies in humans. The research team is now investigating whether the drug combination could be beneficial in advanced stages of MASLD, particularly when liver fibrosis is present. They aim to create dual models encompassing both liver disease and cardiovascular conditions to ascertain the broader implications of their findings.
As they move forward, scientists stress the importance of clinical trials to determine whether the advantages observed in animal studies can translate to human patients. The continued exploration of drug repurposing might just unlock new avenues in the fight against MASLD and its associated risks.
This study reinforces the critical need for effective treatment options for metabolic dysfunction-associated steatotic liver disease, promising both hope and new strategies for managing this widespread health concern.
Original Source: http://www.sciencedaily.com/releases/2026/04/260422003024.htm
Category :
Tags:
Publish Date: 2026-04-22 10:23:00
